发布求助
文献互助 智能选刊 最新文献

Annals of Urologic Oncology最新文献

筛选
英文 中文
Urinary Bladder Leiomyoma Causing Obstructive Uropathy: A Case Report and Literature Review 膀胱平滑肌瘤致梗阻性尿病1例报告并文献复习
Annals of Urologic Oncology Pub Date : 2023-01-27 DOI: 10.32948/auo.2023.01.24
Karthikesh Omkaram, Ramprasad Reddy A, E. Galeti, Surender Reddy, M. Aleem, Gousia Begum S
{"title":"Urinary Bladder Leiomyoma Causing Obstructive Uropathy: A Case Report and Literature Review","authors":"Karthikesh Omkaram, Ramprasad Reddy A, E. Galeti, Surender Reddy, M. Aleem, Gousia Begum S","doi":"10.32948/auo.2023.01.24","DOIUrl":"https://doi.org/10.32948/auo.2023.01.24","url":null,"abstract":"This is the first time a large endovesical leiomyoma of the urinary bladder has been reported in India. A 44-year-old woman had painless gross haematuria, increased urine frequency, an incomplete emptying feeling, and left loin discomfort. Imaging and cystoscopy revealed a 6 x 5 cm projecting endovesical tumour emerging from the bladder's base near the left vesico-ureteric junction. Transurethral bladder resection with few biopsies was performed, histopathological examination revealed a pathological diagnosis of a leiomyoma of the urinary bladder. Intravesical complete excision of the tumor was performed after ligating its pedicle. Complete surgical resection is a very effective treatment, associated with almost no recurrence. We discuss the relevant recent literature of bladder leiomyoma.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47381699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Renal Leiomyosarcoma: Case Report and Review of the Literature 原发性肾平滑肌肉瘤病例报告及文献复习
Annals of Urologic Oncology Pub Date : 2023-01-09 DOI: 10.32948/auo.2023.01.28
Sunil V. Jagtap, Shubham S. Jagtap, Kaushiki Varshney, Y. Jadhav, P. Shah
{"title":"Primary Renal Leiomyosarcoma: Case Report and Review of the Literature","authors":"Sunil V. Jagtap, Shubham S. Jagtap, Kaushiki Varshney, Y. Jadhav, P. Shah","doi":"10.32948/auo.2023.01.28","DOIUrl":"https://doi.org/10.32948/auo.2023.01.28","url":null,"abstract":"Renal leiomyosarcoma is an extremely rare malignant tumor. On clinical presentation and radio imaging it is challenging to make an accurate preoperative diagnosis. In our case, a 59-year-old female presented with history of left-sided flank pain, intermittent hematuria and weight loss of 6 months duration. She was known case of hypertension and diabetes mellitus of 20 years and on regular treatment. On the abdomino-pelvis sonography showed an exophytic cortical mass lesion measuring 4.0 x 3.8 cm lesion. Magnetic resonance imaging abdomen and pelvis (plain) shows a well defined non encapsulated exophytic predominantly solid mass lesion measuring 4.3 x 4 x 4.5 cm is noted in the anterior cortex of left kidney at interpolar region. There was no evidence of any regionalor distant metastesis. Patient underwent left radical nephrectomy. On histopathology reported as renal leiomyosarcoma. Immuhistochemistry showed smooth muscle actin diffusely and desmin focally positive. We present this review of rare case of primary renal leiomyosarcoma for its clinical presentation, radiographic findings, and pathologic features.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47555586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 and Prostate Cancer, Can Two Negatives Equal a Positive? COVID-19和前列腺癌，两个阴性等于阳性吗?
Annals of Urologic Oncology Pub Date : 2023-01-03 DOI: 10.32948/auo.2023.01.01
Cade C. Lewis, Aidan J. Heslin, Cole R. Formslag, Mark R. Wakefield, Yujiang Fang
{"title":"COVID-19 and Prostate Cancer, Can Two Negatives Equal a Positive?","authors":"Cade C. Lewis, Aidan J. Heslin, Cole R. Formslag, Mark R. Wakefield, Yujiang Fang","doi":"10.32948/auo.2023.01.01","DOIUrl":"https://doi.org/10.32948/auo.2023.01.01","url":null,"abstract":"This is a letter to the editor on the discussion on COVID-19 and prostate cancer.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44751719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 Vaccine and Bladder Cancer: Friend or Foe? COVID-19疫苗与膀胱癌:是敌是友?
Annals of Urologic Oncology Pub Date : 2022-12-31 DOI: 10.32948/auo.2022.12.30
Kevin Z. Qi, Miriam P. Palomino, Justin D. Murray, Madeline N. Agee, M. Wakefield, Yujiang Fang
{"title":"COVID-19 Vaccine and Bladder Cancer: Friend or Foe?","authors":"Kevin Z. Qi, Miriam P. Palomino, Justin D. Murray, Madeline N. Agee, M. Wakefield, Yujiang Fang","doi":"10.32948/auo.2022.12.30","DOIUrl":"https://doi.org/10.32948/auo.2022.12.30","url":null,"abstract":"This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45460696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Advance Prostate Cancer 癌症进展的最新进展
Annals of Urologic Oncology Pub Date : 2022-12-30 DOI: 10.32948/auo.2022.12.29
Nishant Lohia
{"title":"Recent Advances in Advance Prostate Cancer","authors":"Nishant Lohia","doi":"10.32948/auo.2022.12.29","DOIUrl":"https://doi.org/10.32948/auo.2022.12.29","url":null,"abstract":"Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy besides androgen deprivation therapy. Varied newer drugs and combinations in recent years have improved the outcome of prostate cancer in terms of both overall survival(OS) and metastases free survival(MFS). Some of the latest drugs which have cleared regulatory approval are Abiraterone, Enzalutamide,Apulatamide, Sipuleucel-T etc. However still more needs to be explored to negate and overcome the resistant mechanisms. Here in this article we have summarized the varied newer and recent developments in advanced prostate cancer.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47106106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoepitheliomatous Hyperplasia: Harbinger of Underlying Squamous Cell Carcinoma - Lessons Learnt 假上皮瘤样增生：潜在鳞状细胞癌的先兆——经验教训
Annals of Urologic Oncology Pub Date : 2022-12-25 DOI: 10.32948/auo.2022.12.22
S. Krishnamoorthy, H. Sekar, L. Joseph, J. Kumar
{"title":"Pseudoepitheliomatous Hyperplasia: Harbinger of Underlying Squamous Cell Carcinoma - Lessons Learnt","authors":"S. Krishnamoorthy, H. Sekar, L. Joseph, J. Kumar","doi":"10.32948/auo.2022.12.22","DOIUrl":"https://doi.org/10.32948/auo.2022.12.22","url":null,"abstract":"Pseudoepitheliomatous hyperplasia (PEH) is a benign condition marked by reactive epithelial proliferation seen in response to various insults like trauma, infection, persistent inflammation and neoplasia. In this report, we discuss a case of a 35-year-old man who presented with a perineal swelling, later turned into a non-healing ulcer, first diagnosed as PEH. Still, after clinical suspicion, a deeper biopsy was conducted, confirming the diagnosis of squamous cell carcinoma and directing treatment appropriately.\u0000Non-healing perineal lesions are not uncommon. Most of the lesions turn out to be Squamous Cell Carcinoma. But, if the histopathological picture suggests Pseudoepitheliomatous Hyperplasia, it is vital to consider the limitations of the biopsy, and a solid clinicopathological correlation is required to look aggressively for underlying Squamous Cell Carcinoma. Due to the benign nature of PEH, most cases are treated via excision biopsy, while grafts or flaps are occasionally required to restore severe tissue defects.\u0000It is therefore crucial to rule out and distinguish this condition from other benign and malignant conditions, as the treatment and prognosis differ widely. It is of utmost importance to sample the base of the lesion, analyze multiple sections, and consider clinical data to ensure an accurate diagnosis.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43391710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma 靶向CTLA-4治疗癌症:以肾细胞癌为重点的生物学见解
Annals of Urologic Oncology Pub Date : 2022-12-20 DOI: 10.32948/auo.2022.12.15
Juan Wu, Yang Ren, Jun Xie, Dong-sheng Li
{"title":"Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma","authors":"Juan Wu, Yang Ren, Jun Xie, Dong-sheng Li","doi":"10.32948/auo.2022.12.15","DOIUrl":"https://doi.org/10.32948/auo.2022.12.15","url":null,"abstract":"Renal cell carcinoma (RCC) is a complex group of malignant tumors characterized by immunosuppression and high invasiveness. In the majority of patients with advanced renal cell carcinoma, treatment fails to achieve a complete cure post-treatment. Efforts are needed to develop new therapeutics to improve the outcome of renal cell carcinoma. The \"immune checkpoint\" of T cells has attracted much attention in tumor immunotherapy. It is widely accepted that suppressor T cell immune checkpoints promote tumor immune escape through negative immune regulatory signals (cytotoxic T lymphocyte associated antigen 4 [CTLA-4], programmed cell death 1 [PD-1], B7-H3, and B7-H4, among others). The current data suggest that the PD-1 and CTLA-4 receptors inhibit the T cell receptor and its proliferation. Blockade of the PD-I/PD-L1 and/or CTLA-4/CD 28 pathways has shown favorable tumor outcomes in clinical trials in advance-stage renal cancer. This article reviews the role of CTLA-4/CD 28 pathway in renal cell carcinoma. Here we discuss the basics of the CTLA-4 pathway from a physiological perspective and evaluate the results of clinical studies of CTLA-4 alone and in combination with PD-1/PD-L1 blockers to support future studies of combination immunotherapy.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43891157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma 脱铁性贫血作为肾癌治疗策略的研究进展
Annals of Urologic Oncology Pub Date : 2022-12-16 DOI: 10.32948/auo.2022.12.09
Liu Minna, Min Bai, N. Cui, Yi Ding, Peng Zhang
{"title":"Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma","authors":"Liu Minna, Min Bai, N. Cui, Yi Ding, Peng Zhang","doi":"10.32948/auo.2022.12.09","DOIUrl":"https://doi.org/10.32948/auo.2022.12.09","url":null,"abstract":"Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent studies revealed the involvement of ferroptosis metabolism, lipid peroxidation, and System XC-GSH-GPX4 shafts as major mechanisms closely related to RCC progression. Nanoparticles in combination with small molecular ferroptosis induction agents have the advantages of solubility, targeted enhancement, low systemic toxicity, controllable drug control, and synergy advantage in emerging combination therapies. In the future, it is possible to be used in nano treatment. The relationship between ferroptosis-related mechanisms and RCC progression and its role in the treatment could provide novel treatment strategies for patients with advance-stage RCC.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49379444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin 长非编码RNA INE1诱导自噬促进前列腺癌症细胞对顺铂的敏感性
Annals of Urologic Oncology Pub Date : 2022-11-29 DOI: 10.32948/auo.2022.11.24
Hezhen Chu, Kongdong Li, Jie Gu, Wen-chao Xie, Yimin Xie, Jun Ma
{"title":"Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin","authors":"Hezhen Chu, Kongdong Li, Jie Gu, Wen-chao Xie, Yimin Xie, Jun Ma","doi":"10.32948/auo.2022.11.24","DOIUrl":"https://doi.org/10.32948/auo.2022.11.24","url":null,"abstract":"Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1) with the characterization in prostate cancer patients, and detected the roles of INE1 in cell autophagy and apoptosis in prostate cancer cells. Our results showed that the lncRNA INE1 expression highly correlate with patients’ survival times, tumor stage, biochemical recurrence, disease recurrence and Gleason pattern. High expression of INE1 was detected in prostate cancer cells, and knockdown INE1 by siRNA resulted in significant inhibition of cell viability. In addition, silencing INE1 induced early autophagy and pro-apoptosis, which augments cisplatin (CDDP)-induced cell apoptosis. Moreover, INE1 played an anti-apoptotic role by targeting the serine/arginine-rich splicing factor 2 (SRSF2).","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41586571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Non-Coding RNA FAM66C Promotes Prostate Cancer Metastasis via JNK-Mediated Proteasome and Lysosomal Pathway 长链非编码RNA FAM66C通过jnk介导的蛋白酶体和溶酶体途径促进前列腺癌转移
Annals of Urologic Oncology Pub Date : 2022-11-29 DOI: 10.32948/auo.2022.11.23
Zhenqian Qin, Kongdong Li, Jie Gu, Yimin Xie, Xuefeng Yuan
{"title":"Long Non-Coding RNA FAM66C Promotes Prostate Cancer Metastasis via JNK-Mediated Proteasome and Lysosomal Pathway","authors":"Zhenqian Qin, Kongdong Li, Jie Gu, Yimin Xie, Xuefeng Yuan","doi":"10.32948/auo.2022.11.23","DOIUrl":"https://doi.org/10.32948/auo.2022.11.23","url":null,"abstract":"Purpose To identify the role of long non-coding RNA FAM66C in the metastatic progression of prostate cancer cells and its underlying mechanisms.\u0000Methods The Cancer Genome Atlas (TCGA) data was utilized to determine the relative expression of lncRNA FAM66C in prostate cancer patients with lymph node metastasis. Knockdown FAM66C by siRNA was performed to investigate the effects of FAM66C in cell migration and epithelial-mesenchymal transition (EMT) by wound healing assay and Western blotting. The proteasome inhibitor MG132 and lysosomal inhibitor chloroquine (CQ) were used to determine the effect of these pathways in FAM66C-regulated cell migration. The c-jun-N-Terminal Kinase (JNK) inhibitor SP600125 was used to identify the role of JNK signaling in FAM66C-regulated cell migration and the proteasome and lysosome pathways.\u0000Results A lower expression of lncRNA FAM66C was noted in the most prostate cancer patients. Knockdown of FAM66C in human prostate cancer DU145 and PC-3 cells promoted EMT and cell migration, which was suppressed by proteasomal inhibitor MG132 and lysosomal inhibitor CQ. Knockdown of FAM66C induced JNK signaling, cell migration and invasion, and activation of proteasome and lysosome pathways were suppressed by JNK inhibitor SP600125.\u0000Conclusion This study provided new evidence of the role of lncRNA FAM66C in the regulation of JNK signaling mediated proteasome and lysosome pathways affecting migration ability of prostate cancer cells.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42672162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信